Showing results (771-780 of 857) with videos related to
Sort By:
Pageof 86
Hypertension (Dallas, Tex. : 1979)|June 28, 2022
Association of Blood Pressure-Related Increase in Vascular Stiffness on Other Measures of Target Organ Damage in YouthJessica E Haley, Shalayna A Woodly, Stephen R Daniels, et al.Drugs in R&D|August 24, 2017
Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled TrialDavid J Webb, Blai Coll, Hiddo J L Heerspink, et al.European Journal of Preventive Cardiology|August 1, 2015
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markersBauke Schievink, Dick de Zeeuw, Paul A Smink, et al.The New England Journal of Medicine|September 17, 2010
Erythropoietic response and outcomes in kidney disease and type 2 diabetesScott D Solomon, Hajime Uno, Eldrin F Lewis, et al.Plos Medicine|April 6, 2019
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trialNorberto Perico, Piero Ruggenenti, Annalisa Perna, et al.Blood|August 19, 2020
Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working groupFadi Fakhouri, Marie Scully, François Provôt, et al.Iscience|September 21, 2023
A GWAS in the pandemic epicenter highlights the severe COVID-19 risk locus introgressed by NeanderthalsMatteo Breno, Marina Noris, Nadia Rubis, et al.Journal of the American Heart Association|October 28, 2025
A Multiomics Approach to Defining Target-Organ Injury in Youths With Primary Hypertension: The SHIP AHOY CohortKalyani Ananthamohan, Tammy M Brady, Mohammed Arif, et al.Kidney International|June 5, 2014
Taming the chronic kidney disease epidemic: a global view of surveillance effortsJai Radhakrishnan, Giuseppe Remuzzi, Rajiv Saran, et al.Plos Medicine|July 14, 2021
Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) studyPiero Ruggenenti, Monica Cortinovis, Aneliya Parvanova, et al.Pageof 86